The impact of steatotic liver disease on coronary artery disease through changes in the plasma lipidome.
Atherosclerosis
Fatty acid
Glycerophospholipids
LDL
Lipidomics
Mediation analysis
Sphingolipids
Triglycerides
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
08
02
2024
accepted:
17
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
27
9
2024
Statut:
epublish
Résumé
Steatotic liver disease has been shown to associate with cardiovascular disease independently of other risk factors. Lipoproteins have been shown to mediate some of this relationship but there remains unexplained variance. Here we investigate the plasma lipidomic changes associated with liver steatosis and the mediating effect of these lipids on coronary artery disease (CAD). In a population of 2579 Swedish participants of ages 50 to 65 years, lipids were measured by mass spectrometry, liver fat was measured using computed tomography (CT), and CAD status was defined as the presence of coronary artery calcification (CAC score > 0). Lipids associated with liver steatosis and CAD were identified and their mediating effects between the two conditions were investigated. Out of 458 lipids, 284 were found to associate with liver steatosis and 19 of them were found to also associate with CAD. Two fatty acids, docosatrienoate (22:3n6) and 2-hydroxyarachidate, presented the highest mediating effect between steatotic liver disease and CAD. Other mediators were also identified among sphingolipids and glycerophospholipids, although their mediating effects were attenuated when adjusting for circulating lipoproteins. Further research should investigate the role of docosatrienoate (22:3n6) and 2-hydroxyarachidate as mediators between steatotic liver disease and CAD alongside known risk factors.
Identifiants
pubmed: 39333359
doi: 10.1038/s41598-024-73406-8
pii: 10.1038/s41598-024-73406-8
doi:
Substances chimiques
Lipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22307Informations de copyright
© 2024. The Author(s).
Références
Baratta, F. et al. Heterogeneity of non-alcoholic fatty liver disease (NAFLD): implication for cardiovascular risk stratification. Atherosclerosis. 357, 51–59 (2022).
doi: 10.1016/j.atherosclerosis.2022.08.011
pubmed: 36058083
Liu, J. et al. Fatty liver, abdominal adipose tissue and atherosclerotic calcification in African americans: the Jackson Heart Study. Atherosclerosis. 224 (2), 521–525 (2012).
doi: 10.1016/j.atherosclerosis.2012.07.042
pubmed: 22902209
pmcid: 3459068
Mellinger, J. L. et al. Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham Heart Study. J. Hepatol.63 (2), 470–476 (2015).
doi: 10.1016/j.jhep.2015.02.045
pubmed: 25776891
pmcid: 5282653
Al Rifai, M. et al. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 239 (2), 629–633 (2015).
doi: 10.1016/j.atherosclerosis.2015.02.011
pubmed: 25683387
pmcid: 4406399
VanWagner, L. B. et al. Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the coronary artery risk development in young adults study. Atherosclerosis. 235 (2), 599–605 (2014).
doi: 10.1016/j.atherosclerosis.2014.05.962
pubmed: 24956534
pmcid: 4124046
Gummesson, A. et al. Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: a cross-sectional, population-based study in middle-aged subjects. PLoS One. 13 (8), e0202666 (2018).
doi: 10.1371/journal.pone.0202666
pubmed: 30133541
pmcid: 6105021
DeFilippis, A. P. et al. Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis. Atherosclerosis. 227 (2), 429–436 (2013).
doi: 10.1016/j.atherosclerosis.2013.01.022
pubmed: 23419204
pmcid: 4049078
Deprince, A., Haas, J. T. & Staels, B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol. Metab.42, 101092 (2020).
doi: 10.1016/j.molmet.2020.101092
pubmed: 33010471
pmcid: 7600388
Björnson, E. et al. Mediating role of atherogenic lipoproteins in the relationship between liver fat and coronary artery calcification. Sci. Rep.13 (1), 13217 (2023).
doi: 10.1038/s41598-023-39390-1
pubmed: 37580332
pmcid: 10425432
Schmidt, C., Gummesson, A., Bäckhed, F., Bergström, G. & Söderberg, M. Psychosocial work conditions and prediabetes risks: a cross-sectional study in middle-aged men and women. Sci. Rep.13 (1), 1198 (2023).
doi: 10.1038/s41598-023-28420-7
pubmed: 36681698
pmcid: 9867778
Bergström, G. et al. The Swedish CArdioPulmonary BioImage Study: objectives and design. J. Intern. Med.278 (6), 645–659 (2015).
doi: 10.1111/joim.12384
pubmed: 26096600
pmcid: 4744991
Kullberg, J. et al. Automated analysis of liver fat, muscle and adipose tissue distribution from CT suitable for large-scale studies. Sci. Rep.7 (1), 10425 (2017).
doi: 10.1038/s41598-017-08925-8
pubmed: 28874743
pmcid: 5585405
Bergström, G. et al. Prevalence of subclinical coronary artery atherosclerosis in the General Population. Circulation. 144, 916–929 (2021).
doi: 10.1161/CIRCULATIONAHA.121.055340
pubmed: 34543072
pmcid: 8448414
McCollough, C. H. et al. Coronary artery calcium: a multi-institutional, multimanufacturer international standard for quantification at cardiac CT. Radiology. 243 (2), 527–538 (2007).
doi: 10.1148/radiol.2432050808
pubmed: 17456875
Evans, A. M. et al. Nontargeted Ultrahigh Performance Liquid Chromatography/Electrospray Ionization Tandem Mass Spectrometry Platform for the identification and relative quantification of the small-molecule complement of Biological systems. Anal. Chem.81 (16), 6656–6667 (2009).
doi: 10.1021/ac901536h
pubmed: 19624122
Imai, K., Keele, L., Tingley, D. & Yamamoto, T. (eds) Causal mediation analysis using R. in Advances in Social Science Research Using R. (Springer, New York, NY, 2010).
Puri, P. et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology. 50 (6), 1827–1838 (2009).
doi: 10.1002/hep.23229
pubmed: 19937697
Gorden, D. L. et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J. Lipid Res.56 (3), 722–736 (2015).
doi: 10.1194/jlr.P056002
pubmed: 25598080
pmcid: 4340319
Kalhan, S. C. et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism. 60 (3), 404–413 (2011).
doi: 10.1016/j.metabol.2010.03.006
pubmed: 20423748
Barr, J. et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J. Proteome Res.11 (4), 2521–2532 (2012).
doi: 10.1021/pr201223p
pubmed: 22364559
pmcid: 3321123
Bissig-Choisat, B. et al. A human liver chimeric mouse model for non-alcoholic fatty liver disease. JHEP Rep.3 (3), 100281 (2021).
doi: 10.1016/j.jhepr.2021.100281
pubmed: 34036256
pmcid: 8138774
Hliwa, A., Ramos-Molina, B., Laski, D., Mika, A. & Sledzinski, T. The role of fatty acids in non-alcoholic fatty liver disease progression: An update. Int. J. Mol. Sci.22(13), 6900 (2021).
doi: 10.3390/ijms22136900
pubmed: 34199035
pmcid: 8269415
Petriello, M. C. et al. Dioxin-like PCB 126 increases systemic inflammation and accelerates atherosclerosis in lean LDL receptor-deficient mice. Toxicol. Sci.162 (2), 548–558 (2018).
doi: 10.1093/toxsci/kfx275
pubmed: 29216392
Zaghlool, S. B. et al. Metabolic and proteomic signatures of type 2 diabetes subtypes in an arab population. Nat. Commun.13 (1), 7121 (2022).
doi: 10.1038/s41467-022-34754-z
pubmed: 36402758
pmcid: 9675829
Starekova, J., Hernando, D., Pickhardt, P. J. & Reeder, S. B. Quantification of Liver Fat content with CT and MRI: state of the art. Radiology. 301 (2), 250–262 (2021).
doi: 10.1148/radiol.2021204288
pubmed: 34546125